Epicardial Fat Shows Promise as a Clinical Risk Factor for CAD

Why It Matters

EAT volume adds prognostic insight into coronary plaque dynamics, potentially guiding preventive therapy. Its non‑invasive, AI‑driven measurement could refine cardiovascular risk stratification if validated.

Key Takeaways

• High epicardial fat volume predicts plaque progression.
• EAT volume linked to rapid plaque progression, not MACE.
• AI-driven CT quantifies EAT quickly for risk assessment.
• Statins and GLP‑1 agonists may reduce epicardial fat.
• Clinical adoption limited; more outcome studies required.

Pulse Analysis

Epicardial adipose tissue, the fat depot nestled between the myocardium and the visceral pericardium, has attracted attention for its paracrine influence on coronary arteries. Unlike subcutaneous fat, EAT shares microcirculation with the myocardium, allowing inflammatory cytokines to directly affect atherosclerotic processes. Advances in cardiac computed tomography, especially with artificial‑intelligence segmentation platforms such as QFat, now enable clinicians to extract volumetric EAT measurements from routine scans without additional radiation or contrast. This capability transforms a previously research‑only metric into a potentially scalable risk marker that can be incorporated into existing imaging workflows.

The PARADIGM registry analysis of 773 middle‑aged patients confirmed that higher EAT volume correlates with both any plaque progression and rapid plaque progression, independent of traditional risk factors like BMI, diabetes, and statin use. Although the study did not link EAT directly to major adverse cardiovascular events, the observed decline in ten‑year MACE‑free survival among patients with progressing plaque underscores the prognostic relevance of plaque dynamics. Importantly, the AI‑driven quantification was rapid and reproducible, positioning EAT as a modifiable target; early data suggest statins and GLP‑1 receptor agonists may attenuate epicardial fat accumulation.

Despite these promising signals, widespread clinical adoption faces hurdles. Cardiologists must demonstrate that adding EAT volume to existing tools—coronary calcium scoring, fractional flow reserve CT, and plaque characterization—improves event prediction beyond current standards. Ongoing trials should focus on whether therapeutic interventions that lower EAT translate into measurable reductions in plaque progression and hard outcomes. Reimbursement pathways will likely follow evidence of cost‑effectiveness, as seen with calcium scoring. If future research confirms its incremental value, EAT quantification could become a routine component of precision cardiology, offering a non‑invasive window into both disease burden and treatment response.